BCOR is a gene that encodes for an epigenetic regulator involved in the specification of cell
differentiation and body structure development and takes part in the noncanonical polycomb …

Recent advances in cancer characterization have consistently revealed marked
heterogeneity, impeding the completion of integrated molecular and clinical maps for each …

More than 50 subtypes of B-cell non-Hodgkin lymphoma (B-NHL) are recognized in the most
recent World Health Organization classification of 2016. The current treatment paradigm …

PURPOSE In previous analyses of the MURANO study, fixed-duration venetoclax plus
rituximab (VenR) resulted in improved progression-free survival (PFS) compared with …

SF3B1 is the most commonly mutated RNA splicing factor in cancer,,–, but the mechanisms
by which SF3B1 mutations promote malignancy are poorly understood. Here we integrated …

Pancreatic ductal adenocarcinoma (PDAC) is driven by co-existing mutations in KRAS and
TP53. However, how these mutations collaborate to promote this cancer is unknown. Here …

Complex karyotype identified by chromosome-banding analysis has been shown to have
prognostic value in chronic lymphocytic leukemia (CLL). Genomic arrays offer high …

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in
chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 …

Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy
remains a central treatment modality, with chemotherapy trials representing an invaluable …

Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is
the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of …